EDAP Key Statistics, Chart & Performance
The current stock price of EDAP is 3.21 USD. In the past month the price increased by 37.77%. In the past year, price increased by 28.92%.
EDAP Competitors/Peers
Symbol | Company Name | TA | FA | PE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 25.21 | 218.72B | ||
| ISRG | INTUITIVE SURGICAL INC | 66.51 | 203.00B | ||
| BSX | BOSTON SCIENTIFIC CORP | 32.55 | 142.33B | ||
| SYK | STRYKER CORP | 26.89 | 135.42B | ||
| BDX | BECTON DICKINSON AND CO | 13.57 | 55.84B | ||
| IDXX | IDEXX LABORATORIES INC | 54.11 | 54.48B | ||
| EW | EDWARDS LIFESCIENCES CORP | 33.54 | 50.02B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 18.15 | 37.96B | ||
| RMD | RESMED INC | 24.55 | 35.48B | ||
| DXCM | DEXCOM INC | 36.05 | 26.15B | ||
| PODD | INSULET CORP | 62.81 | 20.19B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.22 | 17.99B |
Related stock screener links
About EDAP
Company Profile
EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. The company is headquartered in Vaulx-En-Velin, Auvergne-Rhone-Alpes and currently employs 310 full-time employees. The firm's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. The company specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. The company also operates worldwide via a network of corporate offices, subsidiaries and distribution partners
Company Info
EDAP TMS SA -ADR
4, rue du Dauphine, PA La Poudrette Lamartine
Vaulx-en-Velin AUVERGNE-RHONE-ALPES 69120 FR
CEO: Marc Oczachowski
Employees: 310
Phone: 33472153150
EDAP TMS SA -ADR / EDAP FAQ
What does EDAP do?
EDAP TMS SA is a holding company, which, through its subsidiary, engages in the development, production, and marketing of minimally invasive medical devices for urological diseases. The company is headquartered in Vaulx-En-Velin, Auvergne-Rhone-Alpes and currently employs 310 full-time employees. The firm's activity is organized in two divisions: HIFU (High Intensity Focused Ultrasound) and ESWL (Extracorporeal ShockWave Lithotripsy) that invests in research and development, partnering with INSERM French public laboratory and international medical research institutions. The company specialises in HIFU technology, a non-invasive treatment of prostate conditions with a range of Robotic HIFU devices, Ablatherm Fusion and Focal One, ESWL and Stone Laser that offers a range of minimally invasive solutions covering the full scope of urinary tract stone indications. The company also operates worldwide via a network of corporate offices, subsidiaries and distribution partners
What is the stock price of EDAP TMS SA -ADR today?
The current stock price of EDAP is 3.21 USD. The price decreased by -0.62% in the last trading session.
What is the dividend status of EDAP TMS SA -ADR?
EDAP does not pay a dividend.
What is the ChartMill rating of EDAP TMS SA -ADR stock?
EDAP has a ChartMill Technical rating of 9 out of 10 and a ChartMill Fundamental rating of 1 out of 10.
How is the valuation of EDAP TMS SA -ADR (EDAP) based on its PE ratio?
EDAP TMS SA -ADR (EDAP) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.61).
What is the employee count for EDAP stock?
EDAP TMS SA -ADR (EDAP) currently has 310 employees.
EDAP Technical Analysis
ChartMill assigns a technical rating of 9 / 10 to EDAP. When comparing the yearly performance of all stocks, EDAP is one of the better performing stocks in the market, outperforming 91.14% of all stocks.
EDAP Fundamental Analysis
ChartMill assigns a fundamental rating of 1 / 10 to EDAP. Both the profitability and financial health of EDAP have multiple concerns.
EDAP Financial Highlights
Over the last trailing twelve months EDAP reported a non-GAAP Earnings per Share(EPS) of -0.61. The EPS increased by 11.86% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -31.94% | ||
| ROE | -84.17% | ||
| Debt/Equity | 0.26 |
EDAP Forecast & Estimates
9 analysts have analysed EDAP and the average price target is 5.95 USD. This implies a price increase of 85.36% is expected in the next year compared to the current price of 3.21.
For the next year, analysts expect an EPS growth of -19.68% and a revenue growth -4.57% for EDAP